H.C. Wainwright analyst Douglas Tsao lowered the firm’s price target on Sage Therapeutics to $50 from $55 and keeps a Neutral rating on the shares post the Q3 results.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly